Clinical trials: Mild Alzheimer Disease
Alzheimer Disease
Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)
In the ADDITION-MCI project, patients with a diagnosis of mild cognitive impairment probably caused by Alzheimer's disease will receive plasma exchange.
- Trial name
- ADDITION-MCI (NCT06234436)
- Testing
- Plasma exchenge
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Oslo University Hospital
Alzheimer Disease
Neuropsychological and Neurophysiological Effects of Cognitive Stimulation in Patients With Alzheimer's Disease and Mild Cognitive Impairment
The present study aims to evaluate the effect of cognitive stimulation (CS) in participants with a diagnosis of moderate and mild Alzheimer's disease (AD) and mild cognitive impairment (MCI) compared to control subjects not…
- Trial name
- NCT03784183
- Testing
- Cognitive Stimulation (CS)
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- University of Roma La Sapienza
Alzheimer's Disease
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition…
- Trial name
- AD (NCT02947893)
- Testing
- Nilotinib Capsule(s) Once a Day by Mouth
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Georgetown University
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
STIM+: PET Biomarker Education & Disclosure
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging.
- Trial name
- STIM+ (NCT04818255)
- Testing
- PET Biomarker Disclosure
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Michigan
Mild Cognitive Impairment
Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker
Multi center study of six Memory Clinics in four Nordic countries in validating a prognostic diagnostic investigation of qEEG in Mild Cognitive Impairment (MCI).
- Trial name
- NCT03659643
- Testing
- EEG with SPR analysis
- Where
- Iceland
- Volunteers
- 300 people
- Sponsor
- Jon Snaedal
Alzheimer Disease, Mild Cognitive Impairment
Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
This study seeks to better understand how older adult aging-in-place/long term care decision making and implementation is impacted by age-related changes (e.g.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Long-Term Care Planning
- Trial name
- PYL (NCT03960476)
- Testing
- PlanYourLifespan.org
- Where
- United States
- Volunteers
- 293 people
- Sponsor
- Northwestern University
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
An Objective Assessment Tool for Evaluating Functioning in Older Adults
The Investigators are seeking your consent to participate in research investigating the development of a mobile application that enhances physical and cognitive assessments.
- Trial name
- SPPB++ (NCT06489847)
- Testing
- SPPB++ Application
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Stanford University
Alzheimer Disease
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive…
- Trial name
- NCT06151808
- Testing
- XTR006
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Dementia Alzheimers, Dementia With Lewy Bodies
Dementias and Microbiota Composition: Is Possible to Revert the Dementia Symptoms Reverting the Microbiota Composition?
Dementia is the major cause of disability and dependency among older adults worldwide affecting memory, cognitive abilities and behavior, interfering with one's ability to perform daily lives activities.
- Conditions
- Dementia Alzheimers, Dementia With Lewy Bodies, Parkinson Disease Dementia, Dementia Frontotemporal
- Trial name
- DEM-BIOTA (NCT05943925)
- Testing
- No intervention, Probiotic supplement
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Rovira i Virgili
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Healthy, Mild Cognitive Impairment
Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Controls and Dementia Patients
Previous studies showed that anodal tDCS applied over the dorsolateral prefrontal cortex (DLPFC) improved episodic memory performance, indicating a possible use as an intervention for patients suffering from memory impairments.
- Conditions
- Healthy, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT03227185
- Testing
- real anodal transcranial direct current stimulation (tDCS)
- Where
- Switzerland
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Bern
Alzheimer's Disease
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo.
- Trial name
- NCT01193608
- Testing
- AAB-003 (PF-05236812)
- Where
- 29 sites in United States, South Korea
- Volunteers
- 88 people
- Sponsor
- Pfizer
Mental Health (Depression), Mental Health and General Well-being
Thrive at Home: A Virtual Reality Social Intervention for Older Adults
The goal of this clinical trial is to evaluate whether a virtual reality (VR) based social platform can improve mental health and social connection for older adults who receive in-home care.
- Conditions
- Mental Health (Depression), Mental Health and General Well-being, Loneliness, Well Being
- Trial name
- Thrive at Home (NCT07835568)
- Testing
- Full Virtual Reality Social Intervention, Abbreviated Virtual Reality Social Intervention
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of California, Santa Barbara
Prevention
Management of Dementia With Olive Oil Leaves - GOLDEN
Mild Dementia (Mild Dementia) is a state of mind disorder (memory, reason, attention, concentration, time orientation) with difficulty in the complex activities of everyday life (bank accounts, shopping, transportation, etc).The…
- Trial name
- GOLDEN (NCT04440020)
- Testing
- Beverage of Olive Oil Leaves, Mediterranean Diet
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Aristotle University Of Thessaloniki
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Traumatic Brain Injury
Amyloid Accumulation After Mild Traumatic Brain Injury
There will be 200 participants, who aged 30 years or older with TBI in 1,5,10,15 years ago and GCS=13-15 will be recruited. Another group of 200 participants with the same age and gender and without TBI will be recruited as the…
- Trial name
- NCT01871610
- Testing
- [18F]AV-45 PET amyloid binding imaging
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Mild Cognitive Impairment, Alzheimer Disease
Understanding Brain Mechanisms Involved in Autobiographical Memory
The overall objective of this project is to characterize the spatiotemporal dynamics of brain oscillations underpinning autobiographical memory (ABM) and the modulation of the memory network using non-invasive brain stimulation.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Memory Loss
- Trial name
- NCT05710549
- Testing
- high-density electroencephalography (hdEEG), Transcranial alternating current stimulation (tACS)
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Lucie Bréchet
Alzheimer's Disease
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease. 60% of participants will receive AADvac1 and 40% of participants will receive placebo.
- Trial name
- ADAMANT (NCT02579252)
- Testing
- AADvac1
- Where
- 42 sites in Austria, Czechia and 6 more
- Volunteers
- 208 people
- Sponsor
- Axon Neuroscience SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.